Advertisement
ARVN vs GMAB
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ARVN is a Hold and GMAB is a Hold.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ARVN’s FA Score shows that 1 FA rating(s) are green whileGMAB’s FA Score has 0 green FA rating(s).
- ARVN’s FA Score: 1 green, 4 red.
- GMAB’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ARVN’s TA Score shows that 5 TA indicator(s) are bullish while GMAB’s TA Score has 3 bullish TA indicator(s).
- ARVN’s TA Score: 5 bullish, 2 bearish.
- GMAB’s TA Score: 3 bullish, 7 bearish.
Price Growth
ARVN (@Biotechnology) experienced а +1.92% price change this week, while GMAB (@Biotechnology) price change was -2.07% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +6.30%. For the same industry, the average monthly price growth was +17.40%, and the average quarterly price growth was -0.11%.
Reported Earning Dates
ARVN is expected to report earnings on Jul 31, 2025.
GMAB is expected to report earnings on Aug 07, 2025.
Industries' Descriptions
@Biotechnology (+6.30% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
| ARVN | GMAB | ARVN / GMAB | |
| Capitalization | 580M | 12.6B | 5% |
| EBITDA | -89.3M | 1.35B | -7% |
| Gain YTD | -58.529 | -2.731 | 2,143% |
| P/E Ratio | N/A | 11.91 | - |
| Revenue | 427M | 3.12B | 14% |
| Total Cash | 954M | 3.23B | 30% |
| Total Debt | 10.5M | 143M | 7% |
ARVN | GMAB | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 50 | 50 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 18 Undervalued | 58 Fair valued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 86 | 42 | |
PRICE GROWTH RATING 1..100 | 63 | 61 | |
P/E GROWTH RATING 1..100 | 100 | 93 | |
SEASONALITY SCORE 1..100 | n/a | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
ARVN's Valuation (18) in the Biotechnology industry is somewhat better than the same rating for GMAB (58) in the null industry. This means that ARVN’s stock grew somewhat faster than GMAB’s over the last 12 months.
ARVN's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as GMAB (100) in the null industry. This means that ARVN’s stock grew similarly to GMAB’s over the last 12 months.
GMAB's SMR Rating (42) in the null industry is somewhat better than the same rating for ARVN (86) in the Biotechnology industry. This means that GMAB’s stock grew somewhat faster than ARVN’s over the last 12 months.
GMAB's Price Growth Rating (61) in the null industry is in the same range as ARVN (63) in the Biotechnology industry. This means that GMAB’s stock grew similarly to ARVN’s over the last 12 months.
GMAB's P/E Growth Rating (93) in the null industry is in the same range as ARVN (100) in the Biotechnology industry. This means that GMAB’s stock grew similarly to ARVN’s over the last 12 months.
| ARVN | GMAB | |
|---|---|---|
| RSI ODDS (%) | N/A | 4 days ago 69% |
| Stochastic ODDS (%) | 4 days ago 88% | 4 days ago 60% |
| Momentum ODDS (%) | 4 days ago 75% | 4 days ago 68% |
| MACD ODDS (%) | N/A | 4 days ago 68% |
| TrendWeek ODDS (%) | 4 days ago 77% | 4 days ago 68% |
| TrendMonth ODDS (%) | 4 days ago 72% | 4 days ago 71% |
| Advances ODDS (%) | 4 days ago 80% | 27 days ago 62% |
| Declines ODDS (%) | 7 days ago 82% | 4 days ago 68% |
| BollingerBands ODDS (%) | N/A | 4 days ago 80% |
| Aroon ODDS (%) | 4 days ago 70% | 4 days ago 57% |
Advertisement
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| LIVR | 27.16 | 0.26 | +0.97% |
| Intelligent Livermore ETF | |||
| TSPA | 39.37 | 0.31 | +0.79% |
| T. Rowe Price US Equity Research ETF | |||
| INOV | 32.25 | 0.04 | +0.11% |
| Innovator Intl Dev Pwr Bffr ETF - Nov | |||
| TAIL | 11.88 | -0.06 | -0.46% |
| Cambria Tail Risk ETF | |||
| NAIL | 58.36 | -3.10 | -5.04% |
| Direxion Daily Hmbldrs&Supls Bull 3X ETF | |||
ARVN and
Correlation & Price change
A.I.dvisor indicates that over the last year, ARVN has been loosely correlated with ERAS. These tickers have moved in lockstep 39% of the time. This A.I.-generated data suggests there is some statistical probability that if ARVN jumps, then ERAS could also see price increases.
| Ticker / NAME | Correlation To ARVN | 1D Price Change % | ||
|---|---|---|---|---|
| ARVN | 100% | +0.63% | ||
| ERAS - ARVN | 39% Loosely correlated | -0.69% | ||
| GMAB - ARVN | 38% Loosely correlated | -0.68% | ||
| TECH - ARVN | 37% Loosely correlated | -0.08% | ||
| CRGX - ARVN | 36% Loosely correlated | +1.36% | ||
| ARCT - ARVN | 36% Loosely correlated | +1.17% | ||
More | ||||
GMAB and
Correlation & Price change
A.I.dvisor indicates that over the last year, GMAB has been loosely correlated with ARGX. These tickers have moved in lockstep 40% of the time. This A.I.-generated data suggests there is some statistical probability that if GMAB jumps, then ARGX could also see price increases.
| Ticker / NAME | Correlation To GMAB | 1D Price Change % | ||
|---|---|---|---|---|
| GMAB | 100% | -0.68% | ||
| ARGX - GMAB | 40% Loosely correlated | -0.30% | ||
| ARVN - GMAB | 38% Loosely correlated | +0.63% | ||
| TECH - GMAB | 37% Loosely correlated | -0.08% | ||
| BMRN - GMAB | 37% Loosely correlated | N/A | ||
| IMCR - GMAB | 37% Loosely correlated | +0.82% | ||
More | ||||